The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d
- PMID: 34224270
- DOI: 10.7326/ACPJ202107200-075
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d
Abstract
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021. [Epub ahead of print.] 33882225.
Comment on
-
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21. N Engl J Med. 2021. PMID: 33882225 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical